Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High glucose-primed HUVEC-derived extracellular vesicles encapsulated in microgels boost diabetic ischaemic flap regeneration via HIF-1α/VEGF pathway.

Journal of nanobiotechnology·2026
Same author

Injectable chondroitin sulfate-glycosylated decellularized extracellular matrix microgels activate Wnt/β-Catenin signaling to promote functional muscle regeneration in VML.

Bioactive materials·2026
Same author

Hierarchical microtopology and phase-specific delivery functionally restore ultralong nerve continuity across species.

Science advances·2026
Same author

Development of a vascularized multi-organoid-on-a-chip to model the heart-islet axis in diabetic cardiomyopathy.

Bioactive materials·2026
Same author

Phosphatidylserine-everted erythrocyte membrane vesicles enhance efferocytosis and remodeling of vascular grafts.

Nature communications·2026
Same author

Betaine based organ preservation solution alleviates renal allograft I/R injury by protecting endothelial cells.

Regenerative biomaterials·2026
Same journal

Carbonylative Aminative Suzuki-Miyaura Coupling: Pd-Catalyzed Synthesis of Amides from Vinyl/Aryl Halides and Boronic Acids.

Journal of the American Chemical Society·2026
Same journal

Divergent Asymmetric Synthesis of Glutinosasins A-E.

Journal of the American Chemical Society·2026
Same journal

Ultrastrong Polyketone Hot-Melt Adhesives Enabled by Ni-Catalyzed Carbonylative Polymerization.

Journal of the American Chemical Society·2026
Same journal

Programmable Anomalous Photovoltaics Enabled by Light-Electric Dual-Field Control.

Journal of the American Chemical Society·2026
Same journal

Biomimetic Redox-Mediated Proton Relay in Nanoreactors for Photocatalysis.

Journal of the American Chemical Society·2026
Same journal

The Sulfur Monoxide-Water Complex.

Journal of the American Chemical Society·2026
See all related articles

Related Experiment Video

Updated: May 16, 2026

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

Surface-induced hydrogelation inhibits platelet aggregation.

Wenting Zheng1, Jie Gao, Lijie Song

  • 1State Key Laboratory of Medicinal Chemical Biology and College of Life Sciences, Nankai University, Tianjin 300071, PR China.

Journal of the American Chemical Society
|December 18, 2012
PubMed
Summary
This summary is machine-generated.

A novel tripeptide hydrogelator, Nap-FFG, selectively self-assembles on platelets, inhibiting their aggregation. This discovery opens new avenues for molecular hydrogel applications in medicine and disease control.

More Related Videos

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Related Experiment Videos

Last Updated: May 16, 2026

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Area of Science:

  • Biomaterials Science
  • Nanotechnology
  • Biochemistry

Background:

  • Platelet aggregation is crucial in thrombosis and hemostasis.
  • Molecular hydrogels offer potential for targeted biomedical interventions.
  • Developing selective agents for platelet inhibition is a significant therapeutic goal.

Purpose of the Study:

  • To investigate the selective self-assembly of a tripeptide hydrogelator, Nap-FFG, on platelet surfaces.
  • To evaluate the anti-platelet aggregation efficacy of Nap-FFG.
  • To explore the potential of Nap-FFG in broader biomedical applications.

Main Methods:

  • Synthesis and characterization of tripeptide hydrogelators.
  • In vitro assays for platelet aggregation inhibition (ADP, collagen, thrombin, arachidonic acid).
  • Surface analysis using LC-MS, confocal microscopy, and cryo-TEM.
  • Zeta potential measurements.
  • Cell surface binding studies using NIH 3T3 cells.

Main Results:

  • Nap-FFG selectively self-assembled on human platelets, inhibiting various aggregation pathways with low IC50 values.
  • Other Nap-FFX analogues showed significantly less or no inhibitory activity.
  • Cryo-TEM revealed self-assembled nanofibers around Nap-FFG treated platelets.
  • Nap-FFG showed higher affinity for platelets compared to NIH 3T3 cells, suggesting selective binding.
  • Surface hydrogelation of platelets by Nap-FFG was observed.

Conclusions:

  • Nap-FFG acts as a selective platelet surface hydrogelator, effectively inhibiting platelet aggregation through unknown ligand-receptor interactions.
  • This finding expands the utility of molecular hydrogels for biomedical applications.
  • Nap-FFG presents a novel strategy for potential therapeutic interventions, including combating infectious diseases via pathogen surface hydrogelation.